Introduction diol-mediated proliferation and ER-mediated transcription is strongly supported by in vivo and in vitro studies Cyclins have been identified as positive regulatory subusing anti-estrogens (DeFriend et al., 1994) . Anti-estrounits of a class of protein kinases termed cyclin-depengens inhibit expression of estrogen-regulated genes and dent kinases (CDKs). These protein kinases have been reduce proliferation of ER-positive breast cells, whereas shown to be important regulators of major cell cycle 17␤-estradiol is a mitogen for breast epithelium (Dubik transitions in a number of diverse eukaryotic systems.
and Shiu, 1988; Weisz and Bresciani, 1988 ; DeFriend et In mammalian cells, at least six different cyclin types al., 1994). Here we report an unexpected relationship have been identified, which act at specific stages of the between cyclin D1 and ER, which has important implicacell cycle. A transient accumulation of cyclin proteins tions for our understanding of proliferation of normal results in activation of their CDK partners and subsebreast epithelium and its deregulation in breast cancer. quently in phosphorylation of target proteins (Resnitzky and Reed, 1995; Weinberg, 1995) . These protein phosResults phorylation cascades are thought to play a crucial role in the various cell cycle transitions.
Cyclin D1 Enhances Transcription D-type cyclins are strongly implicated in controlling of ERE-Responsive Genes progression through the G1 phase of the cell cycle.
Independent of a CDK Partner Three closely related human D-type cyclins have been Activation of ERE-containing genes can be elicited in identified (Inaba et al., 1992; Xiong et al., 1992) , all of ER-positive cells by treatment with 17␤-estradiol and which interact with and activate CDK4 and CDK6, alcan be measured by means of a chloramphenicol acetyl though they have specialized functions in distinct cell transferase (CAT) reporter construct with an upstream types (Matsushime et al., 1991; Motokura et al., 1992) .
ERE site in these cells (Klein-Hitpass et al., 1986 , 1988 . Among the D-type cyclins, cyclin D1 has been impliUsing this system, we have investigated the effect of cated most strongly in oncogenesis. Amplification and cyclin D1 in combination with its associated kinase overexpression of the gene encoding cyclin D1 was fre-CDK4 on ERE-responsive transcription in the well-differentiated and estrogen-responsive T47D breast cancer quently observed in several types of human neoplasia, Figure 1 . Cyclin D1 Potentiates ERE-Responsive Gene Transcription in the Presence of 17␤-estradiol (A) The effect of cyclin D1 and its associated kinase activity on ERE-mediated transcription. An ERE-reporter construct was used in transient transfections of T47D breast cancer cells (Klein-Hitpass et al., 1986 , 1988 together with wild-type cyclin D1, CDK4, or with mutants of cyclin D1, which are unable to bind to CDK4 (cyclin D1-KE), or with retinoblastoma protein pRb (cyclin D1-GH) or a catalytic inactive mutant of CDK4 (CDK4-DN). pCMV-luciferase (0.5 g) served as an internal control. The relative CAT activity was calculated by normalizing to the luciferase activity and was divided by the ERE-CAT activity in the presence of 17␤-estradiol (10 nM). (B) The effects of CDKs on regulation of ERE-mediated transcription by cyclin D1. Cyclin D1 (mutants) in combination with CDKs (2.5 g each) were cotransfected with the ERE-reporter construct in T47D cells. The relative CAT activity was calculated by normalizing to the luciferase activity and was divided by the ERE-CAT activity in the presence of 17␤-estradiol (10 nM). (C) The effect of p16 INK4 in ectopic cyclin D1/CDK4 expressing cells on ERE-mediated transcription. One microgram cyclin D1 and CDK4 expression vector was used in an ERE-dependent system, and for p16 INK4 the amount was variable: 1 ϭ 0.5 g; 2 ϭ 1.0 g; 3 ϭ 5.0 g. CAT activities were quantified by a phase separation assay (Seed and Sheen, 1988) and represent an average of three independent transfection studies. The relative CAT activity was calculated by normalizing to the luciferase activity, and was divided by the ERE-CAT activity in the presence of 17␤-estradiol (10 nM). (D) Cyclin D1 does not affect phosphorylation status of ER. ER-negative U2-OS cells were transfected with k-Ras (lane 1), control plasmid (lane 2), HA-epitope tagged ER (lane 3 and 6), HA-ER and cyclin D1 (lane 4 and 7), and HA-ER and dominant negative CDK4 (lane 5 and 8) in the presence (lanes 1-5) and absence (lanes 6-8) of 17␤-estradiol. After transfection, cells were in vivo labeled with [ 32 P]orthophosphate and immunoprecipitated with a monoclonal antibody directed against HA-tag (12CA5).
cell line. Figure 1 shows that cyclin D1 is a strong endid not enhance transcription of ERE-CAT, nor did CDK4 alone ( Figure 1A ). To verify that a CDK was not required hancer of ERE-responsive gene transcription in the presence of 17␤-estradiol (10 nM). The activity of the in this process, a mutant of cyclin D1 (cyclin D1-KE) was used, which carries a mutation in the cyclin box. This ERE-containing reporter construct increased when cotransfected with increasing amounts of cyclin D1 exmutant cyclin D1 fails to bind CDKs and as a result is unable to mediate phosphorylation of pocket proteins pression vector. Up to 7-fold potentiation was seen as compared to its basal level of 17␤-estradiol-activated (Hinds et al., 1994; Beijersbergen et al., 1995) . Like wildtype cyclin D1, the cyclin D1-KE mutant potentiated transcription, which was arbitrarily set at 1 ( Figure 1A ). The importance of the ERE in this effect is supported transcriptional activation of ER in a dose-dependent manner. Cotransfection of CDK4 and cyclin D1-KE did by the fact that cyclin D1 did not stimulate the activity of a reporter construct that lacked an ERE ( Figure 3A) . not influence the cyclin D1 effect on transactivation (Figure 1B) . This finding supports the notion that the effect Cyclin D1 in combination with its kinase partner CDK4 of cyclin D1 on ER is independent of its ability to activate a CDK partner. Consistent with this notion, binding of cyclin D1 to a CDK that lacks intrinsic kinase activity, such as the dominant negative CDK4 mutant (CDK4 DN) or CDK2 (which is not activated by cyclin D1; Ewen et al., 1993) , prevented the stimulatory effect of cyclin D1. In addition, a CDK that cannot bind to cyclin D1, CDC-2, was ineffective in preventing transactivation by cyclin D1 ( Figure 1B ). These data strongly suggest that the kinase activity of any cyclin D1-CDK complex is irrelevant in activating ERE-mediated transcription. Significantly, cotransfection of cyclin D1 and CDK4 with p16 INK4 , a CDK inhibitor that competes with cyclin D1 for binding to CDK4 (Parry et al., 1995) , enhanced transcription to a level comparable with that induced by cyclin D1 alone ( Figure 1C ). Taken together, these data indicate that "free" cyclin D1 can enhance ERE-mediated transcription, whereas CDK-bound cyclin D1 is inactive.
It has recently been shown that ER can be activated by phosphorylation induced by mitogens and/or oncogenes (Kato et al., 1995) . To investigate the ability of cyclin D1 to induce phosphorylation of ER, ER-negative cells were transfected with HA-epitope-tagged ER in combination with cyclin D1 or dominant negative CDK4. Transiently transfected cells were labeled with [ 32 P]-orthophosphate, and lysates were subjected to immu- (cyclin D1-GH) was used. Cyclin D1-GH carries a muta-(C) The effect of cyclin D1 on ERE-TATA-reporter construct. An EREtion in the LXCXE motif, and this mutation renders the TATA-luciferase construct was used in transient transfection studies protein unable to bind to pocket proteins, such as pRB with T47D cells in combination of cyclin D1. The relative luciferase (Dowdy et al., 1993; Hinds et al., 1994) . Figure 1A shows activity was calculated by normalizing to the internal control and that this cyclin D1 mutant enhanced the expression of was divided by ERE-luciferase activity in the absence of estrogen.
the ERE-CAT reporter construct to the same extent as wild-type cyclin D1, indicating that this enhancement of both in the presence and absence of Org 2058. In additranscription was independent of an intact pRB-binding tion, cyclin D1 did not affect glucocorticoid receptormotif in cyclin D1. mediated transcription (data not shown). Thus, cyclin The uniqueness of cyclin D1 among the cyclins in the D1-mediated activation is not general among steroid activation of ERE-mediated transcription is illustrated receptors. To ask whether the cyclin D1 activation of in Figure 2 . Cyclin D1 potentiated ER-mediated tran-ER depends on the promoter context, we generated a scription, whereas the other D type cyclins (which were second reporter construct in which the ERE is upstream expressed at comparable levels, data not shown) did of a core promoter (TATA box only: ERE-TATA-reporter). not. The specific effect of cyclin D1 on ERE-dependent As shown in Figure 2C , cyclin D1 gave similar levels of transcription was further demonstrated by the inability transactivation in the presence and absence of 17␤-of cyclin E, cyclin A, cyclin B1, and cyclin B2 to activate estradiol when tested on a construct containing ERE ER-mediated transactivation. To study whether cyclin sequence linked to a TATA promoter. This result sug-D1 activates transcription mediated by other steroid regests that the cyclin D1 action is not promoter specific. ceptors, we tested the effect of cyclin D1 on the progesterone receptor (PR) using a progesterone response ele-
The Effect of Cyclin D1 on ERE-Responsive ment (PRE)-containing reporter construct ( Figure 2B ).
Transcription Is Hormone Independent As expected, transcription of the PRE-reporter conTo study the contribution of estrogen to the observed struct was induced by a progestin, Org 2058. Cyclin D1 failed, however, to enhance PRE-mediated transcription enhanced transcription of ERE-containing genes by cyclin D1, T47D cells were transiently transfected with cyclin D1 and the ERE-reporter construct, and were maintained in medium with various concentrations of 17␤-estradiol. Figure 3A demonstrates that the activity of the ERE-CAT reporter construct was dramatically enhanced in T47D cells by 17␤-estradiol, as expected. The activity of the ERE-CAT reporter construct, however, was enhanced substantially by cotransfection of cyclin D1 expression vector at all concentrations of 17␤-estradiol tested. In the absence of ligand, cyclin D1 was able to restore the transcriptional activity to levels similar or even higher than obtained with 17␤-estradiol alone ( Figure 3B ). These data indicate that cyclin D1 and estrogen are synergistic in stimulating estrogen-regulated transcription, and that cyclin D1 can also act independently of estrogen in activating ERE-responsive transcription. Therefore, cyclin D1 can substitute for estrogen in activating ER. This may contribute to the mitogen-independent proliferation in cyclin D1-overexpressing cells, which is frequently found in breast tumors (Schuuring et al., 1992; Bartkova et al., 1994; Michalides et al., 1996) . A hormone-independent mechanism of action of cyclin D1 is further supported by experiments with the anti-estrogen 4-hydroxytamoxifen, which binds to the estrogen receptor in a manner that is competitive with estrogen but fails to activate gene transcription (Berry et al., 1990) . Figure 3C shows that 4-hydroxytamoxifen antagonized the effect of 17␤-estradiol on transcriptional activation, but did not prevent transcriptional potentiation by cyclin D1. Also, a pure anti-estrogen ICI 164,384, which blocks both activation functions of ER (AF-1 and AF-2), did not prevent cyclin D1 transactivation. These data indicate that cyclin D1 was effective in activating transcription of ERE-containing genes in cells harboring ERs occupied with 17␤-estradiol, as well as in cells with unliganded ERs.
Cyclin D1 Action Is ER-Mediated
Because estrogen was not required for this cyclin D1 action, the question arose whether ER itself was required for the effect of cyclin D1 on ERE-responsive transcription. Therefore, we used the human osteosarcoma cell line U2-OS and cervical carcinoma cell line HeLa, both of which have negligible levels of ER. Cotransfection of cyclin D1 and the ERE-reporter construct in these cells did not increase ERE-responsive transcription, whereas cotransfection of these genes with human ER expression vector led to activation of the ERE-CAT ( Figure 4A ). As in T47D cells, cyclin D1 stimulated tran- The effect of estrogen and cyclin D1 on ERE-responsive transcription activity. T47D cells were maintained in medium containing various concentrations of 17␤-estradiol, and were transfected with an ERE-reporter construct or a reporter construct that lacked ERE struct, as described in Experimental Procedures. The amount of (⌬ERE) in concert with cyclin D1 expression vector.
cyclin D1 plasmid used for transient transfections was 5 g per (B) Cyclin D1 activates ERE-CAT transcription in 17␤-estradiol free 10 cm plate in (A) and (C), and variable in (B). During the experiment, conditions. T47D cells were transfected with various amounts of cells were maintained in phenol red-free DMEM supplemented with cyclin D1 constructs in the absence of ligand.
insulin (10 g/ml) and transferrin (10 g/ml); cells were treated with (C) Cyclin D1 induces ERE-gene expression by a hormone-indepen-17␤-estradiol (0.1 nM) and/or antiestrogen (100 nM) as indicated. dent mechanism. The effect of cyclin D1 on ERE-responsive tranAfter 40 hr, cells were lysed and assayed for both CAT activity and scription was examined in T47D cells treated with 17␤-estradiol luciferase activity (Promega, Luciferase system). Data are expressed and/or the antiestrogens 4-hydroxytamoxifen and ICI 164,384.
as relative CAT activity compared with basal CAT level in the ab-T47D cells were transfected with ERE-reporter plasmid, cyclin D1 sence of 17␤-estradiol: E2, 17␤-estradiol; D1, cyclin D1; 4HT, transexpression vector, and the internal control pCMV-luciferase con-4-hydroxytamoxifen; ⌬ERE, pCAT lacking ERE. through the ER to enhance transcription of ERE-con-ER, where the transactivational activity in this complex is provided by the hormone-dependent activation domain taining genes. The ER protein levels in U2-OS cells containing transiently expressed cyclin D1 were similar to AF-2 in ER. GAL4-dependent CAT transcription was minimally stimulated when either GAL4-D1 or ER were those seen in cells without cotransfected cyclin D1 (Figure 4B) . Therefore, the enhancement of ERE-responsive transfected separately, as is shown in Figure 5B . CAT activity was significantly increased, however, by GAL4-gene transcription by cyclin D1 was not due to a modulation of ER protein levels. D1 in combination with ER, suggesting an interaction in vivo between cyclin D1 and liganded ER. Consistent with the data obtained in the ERE-CAT assays (Figure Cyclin D1 Binds to (Un)liganded ER In Vivo and In Vitro 1), CDK4 and progesterone receptor (PR-B) act in this in vivo binding assay as a competitor and as a negative Cyclin D1 could well activate ER-mediated transcription through direct binding to ER. When we mixed in vitrocontrol, respectively. To investigate an in vivo binding between cyclin D1 and unliganded ER, we next genertranslated 35 S-methionine labeled human ER with GSTcyclin D1 protein in an in vitro binding assay, we did ated an ER fusion protein containing a herpes simplex virus VP16 activation domain (VP16-ER). Cotransfection indeed observe specific binding of ER to GST-cyclin D1 ( Figure 5A ). Binding was observed both with liganded of two chimeric expression vectors, GAL4-D1 and VP16-ER, in combination with a GAL4-dependent reporter as well as with unliganded receptor (lanes 2 and 3) . To investigate whether cyclin D1 also binds to both liconstruct resulted in a significant increase in transcription of the reporter construct ( Figure 5C ). This result ganded ER and unliganded ER in vivo, we used a mammalian two-hybrid assay. To test the in vivo binding suggests that cyclin D1 interacts with unliganded ER in vivo. between cyclin D1 and liganded ER, a chimeric expression vector harboring cyclin D1 fused to a GAL4 DNA To get an impression of the relative strength of the ER-cyclin D1 and cyclin D1-CDK4 interactions, we perbinding domain (GAL4-D1) was generated and cotransfected with ER and a GAL4-site containing reporter formed transfection studies with GAL4-D1 in combination with VP16-CDK4 ( Figure 5C ). Using the mammalian plasmid into U2-OS cells. Transcription of the reporter construct should be stimulated in the presence of 17␤-two-hybrid system, the relative activity of GAL4-D1/ VP16-CDK4 was increased 3-fold, as compared with estradiol if a complex is formed between GAL4-D1 and (A) The in vitro interaction between cyclin D1 and ER. The in vitro interaction between cyclin D1 fused to glutathione-S-transferase (GST) and 35 S-labeled ER was studied both in the presence and absence of 17␤-estradiol. GST-cyclin D1 or control GST protein were mixed with 35 Slabeled ER and immobilized on glutathion-agarose beads to establish in vitro binding. Lane 1 represents 10% of ER input, lanes 2 and 3 represent the amount of ER bound to GST-cyclin D1, and lanes 4 and 5 represent the amount of ER bound to GST protein.
(B) The in vivo interaction between cyclin D1 and ER in the presence of 17␤-estradiol. The in vivo interaction between cyclin D1 and liganded ER was studied using a mammalian two hybrid assay with a chimeric protein GAL4-D1, which contains the GAL4 DNA binding domain (amino acid 1-147) fused to cyclin D1, in combination with ER that acts as a hormone-activated transcription factor. As a result of protein-protein interaction, hybrid proteins are able to stimulate transcription of a GAL4-dependent reporter construct (G5BCAT). This reporter construct, G5BCAT, contains five GAL4 binding sites 5Ј to the E1B TATA sequence (Kim et al., 1992) . The human steroid progesterone receptor (PR-B) served as negative control. The unliganded ER also did not stimulate CAT transcription (data not shown). (C) The in vivo interaction between cyclin D1 and ER in the presence and absence of 17␤-estradiol. The in vivo interaction between unliganded ER and cyclin D1 was studied using a mammalian two-hybrid assay with two chimeric proteins, VP16-ER (which contains the herpes simplex virus VP16 activation domain fused to ER) and GAL4-D1, in the GAL4 dependent reporter system as described in Figure 5B . GAL4-D1 in combination with VP16-CDK4 and dimerized ER served as positive controls. The results are expressed as average of at least three separate experiments Ϯ SD, and related to CAT activity of a transfection using vector containing GAL4 DNA binding domain in combination of G5BCAT reporter vector in the presence of 10 nM ligand (17␤-estradiol or Org 2058) for panel B and in the absence of ligand for panel C: E 2, 17␤-estradiol; D1, cyclin D1; ER, estrogen receptor; (asterisks)P Յ 0.05. (D) In vivo interaction between cyclin D1 and ER using immunoprecipitation. HA-tagged ER and cyclin D1 were transfected in U2-OS cells and immunoprecipitated using an antibody against HA-epitope tag (12CA5). The HA-ER associated proteins were tested for cyclin D1 by Western blot analysis. The upper part shows HA-tagged ER and (part of) IgH chains, and the lower part shows cyclin D1 protein. GAL4-D1/VP16-ER. This finding suggests that, besides cyclin D1 binding by Western blot analysis. Cotransfection with cyclin D1 resulted in coimmunoprecipitation the binding of cyclin D1 to its kinase partner CDK4, the cyclin D1-ER interaction is of physiological importance.
of cyclin D1 with liganded as well as with unliganded ER. Thus, cyclin D1 physically interacts both with liImmunoprecipitation studies support the in vivo interaction between cyclin D1 and (un)liganded ER ( Figure  ganded and unliganded ER in vivo. 5D). HA-tagged ER constructs were transfected together with cyclin D1 into U2-OS cells and maintained Cyclin D1 Acts through the EF Region of ER In order to localize the ER domain that responds to in 17␤-estradiol-enriched or -free conditions. HA-ER fusion protein was immunoprecipitated and analyzed for cyclin D1, we have used chimeras in which either regions Figure 6 . Involvement of Cyclin D1 in Binding of ER to ERE Sequences (A) Analysis of protein-ERE complexes in response to cyclin D1 and 17␤-estradiol. Extracts were prepared of U2-OS cells transfected with human ER in combination with cyclin D1, and subjected to mobility shift analysis as described in Experimental Procedures. Lanes 1 and 5 show the effect on ERE binding of transfected U2-OS cells with ER, lanes 2 and 6 represent ER and cyclin D1 cotransfectants, lanes 3 and 7 represent ER, cyclin D1, and CDK4 cotransfectants, and lanes 4 and 8 represent ER and CDK4 cotransfectants. Cell extracts were maintained in 10 nM 17␤-estradiol (lanes 1-4) or in 17␤-estradiol free conditions (lanes 5-8).
(B) ER identification of ERE-associated protein complex. Protein identification of ERE-associated complexes was tested by antibody-dependent supershifts using antibodies directed against ER. Lanes 1 and 4 represent ER transfectants, lanes 2, 3, 5, and 6 represent ER and cyclin D1 transfectants in the presence of 17␤-estradiol (lanes 1, 2, 4, and 5) or absence of ligand (lanes 3 and 6). The transfectants were subjected to mobility shift analysis in the presence of ER antibody (lanes 3-6).
(C) Activation of ER by cyclin D1 does not require sequence-specific DNA binding, and cyclin D1 specifically activates the EF region of ER. U2-OS cells were transfected with 1.5 g of a vector encoding full-length ER, AB region of ER or EF region of ER fused to GAL4 DNA binding domain yielding GAL-ER, GAL-ER(AB), and GAL-ER(EF), respectively. Transfection studies were performed together with cyclin D1 expression vector (1.5 g) and G5BCAT reporter vector (3 g), and cells were kept in the presence or absence of 10 nM 17␤-estradiol. The results are expressed as relative CAT activity compared with basal CAT level in the absence of ligand. (D) In vivo binding between cyclin D1 and GAL-ER fusion proteins. Constructs encoding GAL-ER fusion proteins and cyclin D1 were transfected in U2-OS cells in the presence and absence of 17␤-estradiol (E 2), and immunoprecipitated using antibody directed against GAL-tag (sc 577, Santa Cruz). The GAL-ER (full length), GAL-ER(AB), and GAL-ER (EF) associated proteins were tested for cyclin D1 binding by Western blot analysis as indicated. Lanes 2, 4, 6 and 7 represent cyclin D1 transfected cells. Transfection with a construct encoding the GAL4 DNA binding domain (GAL-DBD) together with cyclin D1 served as negative control (lane 7). (E) Direct binding between cyclin D1 and EF-region of ER. Bacterially produced and purified GST-ER(EF) or control GST protein and histagged cyclin D1 (His-D1) were mixed and immobilized on glutathion-agarose beads. Direct in vitro binding was analyzed by Western blotting using monoclonal antibody directed against cyclin D1. Lane 1 represent 1% of input, lanes 2 and 3 represent the amount of His-D1 bound to GST-ER(EF) and lanes 4 and 5 represent the amount of His-D1 bound to GST protein.
A/B (amino acids 1-184) or E/F (amino acids 282-595) correlated with binding to ER, we performed transient transfection experiments ( Figure 6D ). Immunoprecipitawere fused to the GAL4 DNA binding domain, yielding GAL-ER(AB) (Ali et al., 1993) and GAL-ER(EF) (Webster tion of GAL fusion proteins, which contain the AB or EF region of ER, from transiently transfected U2-OS cell et al., 1988) . Using these constructs in a GAL4-dependent reporter system in combination with cyclin D1, we extracts, followed by Western blot analysis using a monoclonal antibody directed against cyclin D1, refound that the GAL-ER(AB) construct did not respond to cyclin D1 ( Figure 6C ). In contrast, cyclin D1 was able vealed that cyclin D1 predominantly binds to the EF region and not, or at least with lower affinity, to the AB to stimulate transactivation by both GAL-ER(EF) and GAL-ER wild-type to the same extent ( Figure 6C ). To region of ER. This binding between cyclin D1 and the C-terminal domain of ER occurred both in the presence ask whether cyclin D1-mediated transactivation of ER as well as in the absence of 17␤-estradiol. The interacassociated with a direct physical interaction between cyclin D1 and ER. Cyclin D1 enhances binding of both tion between the carboxy-terminal region of ER and cyclin D1 was also confirmed in a GST pulldown experiliganded as well as unliganded ER to ERE-sequences. These data support a model in which cyclin D1-ER interment using bacterially produced and purified His-cyclin D1 and GST-ER(EF), containing amino acids 340-595 action triggers ER to undergo an activation step by means of a conformational change. Cyclin D1 interaction ( Figure 6E ). Since no other mammalian proteins were present in this experiment, these data indicate that increases binding of ER to ERE sequences and enhances transactivation of ER. Together, this activity recyclin D1 acts through direct binding to the C-terminal EF region of ER.
sults in a dramatic enhancement of transcription of EREresponsive genes.
In contrast to the current view that receptor activation Cyclin D1 Enhances Binding of ER is dependent on binding its cognate ligand, the present to ERE Sequence study shows that cyclin D1 also activates ER-mediated To investigate whether the cyclin D1 action on transcriptranscription in the absence of ligand. In addition, it was tion was due to enhanced ER binding to ERE, we anarecently shown that EGF, TGF␣, and dopamine also elicit lyzed the binding of ER-ERE complexes in response to ER-dependent transcription of an ERE-containing gene, cyclin D1 using a gel retardation assay. When transiently which was not dependent on estrogens (Ignar-Trowtransfected into U2-OS cells and maintained in 17␤-bridge et al., 1993; O'Malley et al., 1995) . One possible estradiol enriched medium, cyclin D1 increased the mechanism for estrogen receptor activation could be ER binding to ERE sequence 3-fold ( Figure 6A ). Consisphosphorylation of the receptor (Zhang et al., 1994 ; Kato tent with data obtained from ERE- CAT and interaction et al., 1995) . Transcriptional activation by ER can be assays, cyclin D1 in combination with CDK4 was less induced by growth factors through the membrane-assoeffective in stimulating ER binding to ERE sequence. ciated receptor tyrosine kinase-Ras-Raf-MAPK casAnalysis of DNA binding complexes in response to horcade, which enhances the activity of AF-1 site in ER mone deprivation revealed that cyclin D1 stimulated ER molecule via phosphorylation of the Ser-118 residue binding to ERE, which was absent in cells lacking ec- (Kato et al., 1995) . The present study clearly demontopic cyclin D1 ( Figure 6A ). Antibody supershift experistrates that cyclin D1 does not enhance phosphorylation ments of ERE-associated complexes revealed that ER of ER. Instead, our data indicate that cyclin D1 acts is present in these ERE-associated complexes (Figure through direct physical association to activate ER. 6B). Thus, cyclin D1 triggers binding of liganded and Until now, cyclin D1 has been regarded only as a CDK unliganded ER to ERE sequences.
regulator. Via CDK activation, it regulates progression To investigate whether cyclin D1 only acts on ER speof cells through the G1 phase of the cell cycle. Overexcifically bound to an ERE sequence, we used an ER pression of cyclin D1 causes several effects on the cell fused to GAL4 DNA binding domain in a GAL4-depencycle, including a shortening of the G1 interval, an indent reporter system. In this assay, cyclin D1 enhanced crease of G0/G1 transition, and a decrease of G1/G0 GAL4-dependent transcription in a ligand-independent transition (Resnitzky et al., 1994; Resnitzky and Reed, manner (Figure 6C) , indicating that cyclin D1 does not 1995; Zwijsen et al., 1996) . The dual activity of cyclin require sequence-specific DNA binding by ER for activa-D1 as activator of ER and mediator of cell cycle progrestion. These data therefore indicate that cyclin D1 also sion via cdk kinase activity is thus far unique among the affects ER activity by enhancing transactivation by ER.
cyclins. Overexpression of cyclin E also shortens G1, In conclusion, cyclin D1 acts by both enhancing the DNA as does overexpression of cyclin D1 (Resnitzky et al., binding and transactivation capacity of ER. 1994; Resnitzky and Reed, 1995) , but does not affect ER activation. This finding indicates that perturbed G1 Discussion progression and premature S-phase entry on their own do not account for activation of ER, and highlights that The present study establishes a new role for cyclin D1 cyclin D1 acts in this respect via two different mechaas a positive regulator of ER-mediated transcription.
nisms. The transcriptional activation was specific in that of all
In breast tumor cells, several ER variants have been cyclins tested only cyclin D1 could enhance ER-mediidentified (Zhang et al., 1993; Wiltschke and Fuqua, ated transactivation. Furthermore, cyclin D1 could only 1995) . Many of these variants are the results of alternastimulate transactivation by ER and not the PR. Importive mRNA splicing and of point mutations, which usually tantly, activation of ER by cyclin D1 was entirely indeyield truncated products (Wiltschke and Fuqua, 1995) . pendent of CDK binding and did not require occupancy
The ER variants are coexpressed with, and often in exby cognate steroid of the receptor. In normal breast cess of, wild-type ER. In the present study, we have epithelial cells, estrogen receptors are thought to be used the breast tumor T47D cell line in which small levels transcriptionally inactive within the cell before binding of ER variants with exon 2, 3, 5, and 7 deletions are to hormone. Occupancy by hormone results in conforidentified (Wang and Miksicek, 1991; Zhang et al., 1993) . mational change in its cognate receptor protein, which It is very unlikely that the cyclin D1 action is attributed leads to intranuclear translocation and allows associato one of the ER variants in these cells, since cyclin D1 tion with specific DNA sequence in the regulatory region was effective in the ER-negative U2-OS cells transfected of target genes. As a result of ER-ERE binding, transcripwith wild-type ER cDNA expression vector. Furthertion of cis-linked target genes will be stimulated. We more, immunofluoresence studies revealed that these ectopic ER proteins in U2-OS cells are predominately demonstrated that ER transactivation by cyclin D1 is the transfection, cells were maintained in phenol red-free DMEM located in the nucleus, and that cyclin D1 did not moducontaining insulin/transferrin (10 g/ml each) or 10 nM ligand (the late the subcellular localization of ER (data not shown). estrogen 17␤-estradiol or the progestin Org 2058) as indicated.
Thus, it appears that the activation of ER by cyclin D1 is not due to a change in ER translocation to the nucleus.
Transfection Studies
We have determined that the site of cyclin D1 action
The reporter plasmids, ERE-TK-CAT (3 g) containing the ERE from the vitellogenin A2 gene or (PRE) 2-TK-luc, were transiently transis located in the E/F region of liganded as well as unlifected into subconfluent T47D cells using the calcium phosphate ganded ER. Binding of cyclin D1 to this region could precipitation technique (Graham and van der Eb, 1973) . The expresmodulate the binding of accessory protein(s) of ER, insion vectors used in the transient transfection studies were pCMV cluding Hsp90, Hsp70, p60, p23, and proteins of the cyclin D1, cyclin D2, cyclin D3, cyclin A, cyclin E, cyclin B1, cyclin transcriptional machinary (Pratt, 1993) . It is conceivable B2, CDC2, CDK2, CDK4, CDK4-DN, cyclin D1-GH, and cyclin D1-that they assist in the activation of the ER by cyclin D1. KE, which have been described elsewhere (Hinds et al., 1992 (Hinds et al., , 1994 . ER-negative cells were transfected with 0.4 g human ER construct
For instance, Hsp90 promotes a receptor structure that (HEGO; Migliaccio et al., 1991) . After 40 hr, cells were harvested and is capable of ligand binding. Ligand binding could inresuspended in 0.1 M Tris-HCl (pH 8.0), and assayed for luciferase duce a conformational change in the receptor, which in activity (Promega, Luciferase system), ␤-galactosidase activity turn could prevent rebinding of Hsp90, while simultane-(Tropix, galactolight assay), and/or CAT activity (Seed and Sheen, ously allowing receptor dimerization. This Hsp, however, 1988) .
is an unlikely candidate to assist cyclin D1 in ER activaPhosphate Labeling and Immunoprecipitation tion, because (i) it is dissociated from the ER-complex U2-OS cells were transfected in the presence or absence of serum.
after ligand binding, whereas cyclin D1 also activates After 24 hr, cells were incubated for 1 hr in phosphate-free DMEM, the liganded complex; (ii) the subcellular localization followed by incubation in phosphate-free DMEM supplemented with differs between Hsp90 and cyclin D1 (cytoplasm versus 1.0 mCi/ml [ (Musgrove et al., 1994; Zwijsen et al., 1996) . In this context, the present study clearly shows that cyclin D1 can In Vitro Binding Assay also enhance transcription of ER-responsive genes Total bacterial extracts expressing cyclin D1 protein fused to glutawithout assistance of estrogens by stimulating ER bindthione-S-transferase (GST) or GST protein alone were generated ing to ERE-sequences. This cyclin D1 action enables and purified on gluthathione agarose beads.
35 S-methionine labeled cells to bypass the requirement for estrogens and there-ER protein was prepared by in vitro transcription/translation and incubated with 1 g GST-cyclin D1 in ELB (250 mM NaCl, 0.1% NPfore provides a mechanism for estrogen-independent 40, 50 mM Hepes [pH 7.0], and 5 mM EDTA) with 0.5 mM DTT, 1 growth of cyclin D1-overexpressing breast tumor cells mM PMSF, 10 g/ml aprotinin, and 10 g/ml leupeptin, bound to (Schuuring et al., 1992; Bartkova et al., 1994; Michalides gluthathione-agarose beads, washed in ELB, eluted, and fractionet al., 1996) . Our finding that activation of ER by cyclin ated by SDS-polyacrylamide gel electrophoresis.
D1 cannot be inhibited by the anti-estrogen tamoxifen raises the possibility that tamoxifen treatment is ineffec-
GAL4-Dependent Reporter System
tive in cyclin D1-amplified breast cancers. We are curTo generate chimeric proteins, A/B region of ER (amino acid 1-184) or E/F region of ER (282-595), or full-length of ER or cyclin D1
rently performing a retrospective clinical study on breast cDNAs, were inserted in frame downstream of the GAL4 cancer biopsies to investigate this possibility in detail.
DNA binding domain fragment or sequence coding for the acidic activation domain of the Herpes Simplex virus VP16 protein. U2-OS cells were transfected with 1.5 g GAL4-D1, ER, PR-B, and CDK4 Experimental Procedures expression vectors in combination with 10 g G5B-CAT reporter constructs. As an internal control, 0.5 g of pCMV-luciferase plasmid Cell Lines was used in the assays. The CAT activity was corrected for differences Human T47D, HeLa, and U2-OS cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 10% fetal calf serum. During in transfection efficiency by normalizing to luciferase activity.
